FDA Drug recall D-0659-2024
AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rub…
- FDA Drug
- Class III
- ongoing
- Published 2024-09-25
On 2024-09-25 the FDA classified a Class III recall of AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rub… by Rubicon Research Private, citing discoloration.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0659-2024 |
| Classification | Class III |
| Status | ongoing |
| Initiated | 2024-08-24 |
| Published | 2024-09-25 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Rubicon Research Private |
| Distribution | US |
Product
AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01
Reason
Discoloration
Identifiers
| ndc | 72888-047-01 |
|---|---|
| ndc | 72888-048-01 |
| code_info | Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0659-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.